Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease.


Journal

Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 30 09 2020
revised: 20 11 2020
accepted: 23 11 2020
pubmed: 6 12 2020
medline: 5 11 2021
entrez: 5 12 2020
Statut: ppublish

Résumé

Several cases of Pneumocystosis pneumonia (PCP) have been reported in patients with hypercortisolism, mainly in patients with severe ectopic ACTH syndrome (EAS). We report 2 cases of PCP that did not develop until after starting treatment with metyrapone, one of which occurred in an outpatient with Cushing's disease (CD) without pulmonary symptoms before medical treatment for CD. Patient 1 presented as an outpatient with CD and severe hypercortisolism but nonetheless in good general condition. Treatment with metyrapone was started before pituitary surgery. Patient 2 had EAS due to prostate cancer. Respiratory failure in the two patients occurred 4 days and 30 days, respectively, after the start of metyrapone treatment. In both cases, chest CT showed bilateral interstitial infiltrates, and Pneumocystis jirovecii was found on bronchoalveolar lavage (BAL). A literature review was performed to identify risk factors for PCP in patients with CD: we identified 20 other cases of PCP in patients treated for hypercortisolism, including 16 patients with EAS. Ninety percent of patients had free urinary cortisol greater than 6 times the upper limit of normal (ULN). In conclusion, onset of PCP after initiation of anticortisolic therapy is not limited to patients with EAS, and may occur in CD patients with elevated cortisol levels, even if the patient remains in good general condition and has no pulmonary symptoms before treatment. In such patients, routine prophylactic treatment with trimethoprim/sulfamethoxazole (TMP/SMX) should be considered.

Identifiants

pubmed: 33278378
pii: S0003-4266(20)31302-0
doi: 10.1016/j.ando.2020.11.002
pii:
doi:

Substances chimiques

Trimethoprim, Sulfamethoxazole Drug Combination 8064-90-2
Metyrapone ZS9KD92H6V

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-560

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Justine Cristante (J)

Endocrinology Unit, University Hospital Centre Grenoble Alpes, CS 10217, 38043 Grenoble cedex 9, France. Electronic address: jcristante@chu-grenoble.fr.

Marion Lepelley (M)

Pharmacovigilance Unit, University Hospital Centre Grenoble Alpes, CS 10217, 38043 Grenoble cedex 9, France. Electronic address: mlepelley@chu-grenoble.fr.

Michel Mallaret (M)

Pharmacovigilance Unit, University Hospital Centre Grenoble Alpes, CS 10217, 38043 Grenoble cedex 9, France. Electronic address: mmallaret@chu-grenoble.fr.

Agnès Carreau (A)

Endocrinology Unit, Annecy Genevois Hospital Centre, 1, avenue de l'Hôpital, Epagny Metz-Tessy, BP 90074, 74374 Pringy Cedex, France. Electronic address: acarreau@ch-annecygenevois.fr.

Olivier Chabre (O)

Endocrinology Unit, University Hospital Centre Grenoble Alpes, CS 10217, 38043 Grenoble cedex 9, France. Electronic address: olivier.chabre@chu-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH